Table 4. White blood cell (WBC) counts in prostate-specific specimens at baseline (time point V0) and after treatment in patients from the Cipro-500 and Cipro-750 groups that show eradication or persistence of causative pathogens, and serum prostate-specific antigen (PSA) at baseline (V0), on microbiological eradication (VERAD), and at follow-up time points (V6, V12 and V18) in the Cipro-500 and Cipro-750 treatment groups.
| Cipro-500a | Cipro-750b | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specimen | V0 (baseline) (n=170) | Patients with eradication (n=106) | Patients with persistence/superinfection (n=64) | V0 (baseline) (n=97) | Patients with eradication (n=75) | Patients with persistence/superinfection (n=22) | ||||||
| EPS/VB3 | Semen | EPS/VB3 | Semen | EPS/VB3 | Semen | EPS/VB3 | Semen | EPS/VB3 | Semen | EPS/VB3 | Semen | |
| Patients with ≥10 WBC/ | 64 | 66 | 19 | 18 | 20 | 24 | 44 | 45 | 2 | 0 | 2 | 4 |
| specimen | (37.65%) | (38.82%) | (17.92%) | (16.98%) | (31.25%) | (37.50%) | (45.36%) | (46.39%) | (2.67%) | (9.09%) | (18.18%) | |
| Patients with 10 WBC/ | 106 | 104 | 87 | 88 | 44 | 40 | 53 | 52 | 73 | 75 | 20 | 18 |
| specimen | (62.35%) | (61.18%) | (82.08%) | (83.02%) | (68.75%) | (62.50%) | (54.64%) | (53.61%) | (97.33%) | (100.0%) | (90.91%) | (81.82%) |
| χ2 and P, vs.Cipro-750 | 1.52 | 1.45 | 9.96 | 14.14 | 4.22 | 2.78 | // | // | // | // | // | // |
| cohort | (0.21) | (0.22) | (0.0015) | (0.00016) | (0.039) | (0.095) | ||||||
| Mean/Median WBC/specimen | 10.85/7.0 | 10.33/9.0 | 5.43/4.0 | 5.32/5.0 | 8.19/5.0 | 9.53/7.5 | 11.20/8.0 | 9.56/9.0 | 2.59/2.0 | 2.48/2.0 | 5.50/4.0 | 7.00/5.0 |
| P vs. Cipro-750 cohortc | 0.14 | 0.85 | 0.0002 | <0.0001 | 0.33 | 0.06 | // | // | // | // | // | // |
| P vs. baseline values (V0)d | // | // | <0.0001 | <0.0001 | >0.05 | >0.05 | // | // | <0.0001 | <0.0001 | >0.05 | >0.05 |
| P vs. patients with bacterial eradicationc | // | // | // | // | 0.007 | 0.008 | // | // | // | // | 0.00012 | 0.0018 |
| Study Time point | V0 (baseline) | VERAD | V6 | V12 | V18 | V0 (baseline) | VERAD | V6 | V12 | V18 | ||
| Mean/Median Serum PSA, (ng/ml) | 2.10/1.22 | 1.93/1.00 | 1.40/0.85 | 1.10/0.80 | 1.12/0.83 | 2.24/1.16 | 1.29/0.82 | 0.92/0.64 | 0.93/0.67 | 0.88/0.59 | ||
| PSA range, (ng/ml) | 0.20-8.50 | 0.10-10.96 | 0.10-12.6 | 0.10-6.46 | 0.10-4.35 | 0.25-8.66 | 0.12-8.16 | 0.10-6.71 | 0.12-6.97 | 0.20-7.50 | ||
| P vs. time point V0d | // | 0.099 | 0.0025 | >0.05 | >0.05 | // | 0.0036 | <0.0001 | >0.05 | >0.05 | ||
| P vs. Cipro-750c | 0.6 | 0.14 | 0.015 | 0.074 | 0.018 | // | // | // | // | // | ||
a
A cohort of patients treated with once-daily 500-mg ciprofloxacin for 6 weeks, combined with azithromycin.
b
A cohort of patients treated with once-daily 500-mg ciprofloxacin for 4 weeks, combined with azithromycin.
c
Wilcoxon rank-sum test;
d
Wilcoxon signed-rank test.